Center For Drug Design

What Center For Drug Design does

The Center for Drug Design (CDD) is an academic drug discovery research center founded in 2002 and embedded within the University of Minnesota College of Pharmacy. It conducts medicinal chemistry, molecular modeling, in vitro assay development, compound screening, drug-like property profiling, and chemical probe design, with research programs spanning HIV, cancer, neurological diseases, dermatological applications, infectious diseases, and medical devices. CDD operates a state-of-the-art Pharmacology Core facility offering ADMET, pharmacokinetic, and LC-MS/MS bioanalytical services to internal and external researchers. The center is led by Founding Director Dr. Robert Vince alongside co-directors Dr. Zhengqiang (ZQ) Wang and Dr. Robert Geraghty, supported by a faculty of approximately 12 named principal investigators and research staff.

CDD's commercial portfolio includes ProteXidine™, a patented biomimetic decoy molecule technology for UV protection and anti-aging launched in partnership with TOPIX Pharmaceuticals; a hyperspectral eye scanner for early Alzheimer's detection co-developed with Retispec; a pre-clinical cyanide antidote with Windgap Medical; and a pipeline of antiviral candidates targeting HIV, Mpox, hepatitis B, and other pathogens. The center's most successful historical product is carbovir (abacavir), which was commercialized by GlaxoSmithKline as Ziagen® and has generated over $600 million in cumulative royalties for the University of Minnesota.

CDD's revenue model combines NIH and federal research grants (including active awards such as R01AI183580 for Mpox at $3.8M over five years and R01AI120860 for HIV capsid-targeting antivirals), technology licensing royalties from pharmaceutical partners, and collaborative research agreements with industry and academic institutions. The center does not sell products directly to consumers; instead, it monetizes discoveries through licensing, royalty streams, and co-development partnerships. It is governed by the Regents of the University of Minnesota as a public state entity and operates from Nils Hasselmo Hall on the UMN Twin Cities campus in Minneapolis.

Name

Center For Drug Design

Legal name

Center for Drug Design, University of Minnesota

Website

https://drugdesign.umn.edu

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Short description

The Center for Drug Design is an academic drug discovery research center at the University of Minnesota College of Pharmacy that develops novel therapeutics for HIV, cancer, neurological diseases, and viral infections, monetizing discoveries through NIH grants, technology licensing, and pharmaceutical industry partnerships.

Ownership category

akta.pro rank

Product category

Academic Pharmaceutical Research

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Academic drug discovery
• Pharmaceutical research
• Antiviral drug development
• Medicinal chemistry services
• ADMET pharmacology testing

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Technology Licensing Royalties: The Center generates royalty income through drug company licensing agreements. The carbovir discovery has generated over $600 million in royalties for the University of Minnesota from sales of Ziagen® by GlaxoSmithKline. Licensing fees support faculty, administrative and research staff, postdoctoral fellows, and facility costs.
2. NIH and Federal Research Grants: The center receives substantial NIH grant funding for drug discovery research. Active grants include R01AI183580 for monkeypox virus ($3.8M over 5 years), R01AI167356 for SARS-CoV-2 antivirals, and R01 AI120860 for HIV capsid-targeting antivirals.
3. Product Revenue (Cosmetic): Partnership with TOPIX Pharmaceuticals to launch ProteXidine® product line for skin health and anti-aging applications.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

The Center for Drug Design is an academic research center that develops novel therapeutic drugs and technologies for HIV, cancer, neurological diseases, viral infections, and dermatological conditions. Its portfolio includes ProteXidine™ biomimetic decoy cosmetics commercialized with TOPIX Pharmaceuticals, hyperspectral retinal imaging for Alzheimer's detection co-developed with Retispec, antiviral drug candidates for HIV/Mpox/HCV, a cyanide antidote in pre-clinical development, and a Pharmacology Core providing ADMET and pharmacokinetic research services.

Product overview

The Center for Drug Design operates as an academic drug discovery research center within the University of Minnesota College of Pharmacy, combining research and scholarship to develop novel therapeutics. The center's portfolio spans multiple product categories: (1) ProteXidine™, a functional cosmetic product commercialized with TOPIX Pharmaceuticals that uses biomimetic decoy molecules for UV protection and anti-aging; (2) a hyperspectral eye scanner co-developed with Retispec for non-invasive Alzheimer's disease detection via retinal imaging; (3) pharmaceutical candidates including a cyanide antidote and antiviral drugs for HIV, Mpox, and hepatitis B; and (4) Pharmacology Core services providing ADMET and pharmacokinetic research support to the scientific community. The center was founded in 2002 and has a track record including the development of Ziagen® (abacavir) for HIV/AIDS marketed by GlaxoSmithKline.

Differentiator

Problem solved

Functional benefit

Brands

• ProteXidine™: A patented functional cosmetic technology using biomimetic decoy molecules to enhance skin's natural ability to mitigate ultraviolet-induced damage and inhibit damage caused by Reactive Oxygen Species (ROS). Commercialized in partnership with TOPIX Pharmaceuticals.
• PRD-Tech™

Products and services

• ProteXidine™ A patented functional cosmetic product featuring a proprietary biomimetic decoy molecule that enhances skin's natural ability to mitigate ultraviolet-induced damage and inhibit damage caused by Reactive Oxygen Species (ROS). Reduces Cyclobutane Pyrimidine Dimers (CPDs) formation and increases clearance of damaged epidermal cells. Commercialized with TOPIX Pharmaceuticals for skin health and anti-aging applications.
• Hyperspectral Eye Scanner (Retispec) Non-invasive hyperspectral retinal imaging technology co-developed with Retispec for early detection and diagnosis of Alzheimer's disease. Captures spectral signatures of amyloid aggregates in the retina, enabling identification of patients at risk before cognitive decline onset.
• Cyanide Antidote A faster-acting and safer antidote for cyanide poisoning under pre-clinical development, working prophylactically to prevent or limit toxicity associated from cyanide exposure. Developed in collaboration with Windgap Medical, with a $3.2 million NIH grant supporting the development of a cyanide antidote autoinjector device.
• Pharmacology Core Services ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity), pharmacokinetic studies, and LC-MS bioanalytical services provided to support medicinal chemistry drug discovery efforts. Equipped with Agilent LC-MS systems and Phoenix WinNonlin software. The Core has supported over 40 peer-reviewed papers and 7 NIH grants since 2014.
• Antiviral Drug Candidates (HIV/Mpox) Novel antiviral drug candidates in development targeting HIV, Mpox (orthopoxvirus), hepatitis B, and other emerging viral pathogens. Includes RNase H inhibitors, capsid targeting compounds, and resolvase inhibitors.

Quantifiable outcome

• Over $600 million in royalty revenue generated for the University of Minnesota from Ziagen® sales
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Texas A&M UniversitycoreStrategic or Co-development Partner · 1 June 2025Dr. Zhengqiang (ZQ) Wang from CDD and Dr. Zhilong Yang from Texas A&M University's College of Veterinary Medicine and Biomedical Sciences received a 5-year, $3.8 million NIH grant to develop antiviral drugs for treating Mpox. This is a collaborative research partnership combining expertise in medicinal chemistry (CDD) with veterinary virology expertise (Texas A&M).
• TOPIX Pharmaceuticals, Inc.coreChannel Partner/ Reseller/ DistributorTOPIX Pharmaceuticals is the industry licensee that has partnered with CDD to launch a line of ProteXidine® products for skin health. This represents a commercial partnership bringing CDD technology to market.
• RetispeccoreTechnology or IntegrationCDD has partnered with Retispec, an imaging company, to commercialize a hyperspectral eye scanner for identifying and diagnosing patients who have, or are at risk for, Alzheimer's disease.
• Topix PharmaceuticalscoreChannel Partner/ Reseller/ DistributorCDD partnered with Topix Pharmaceuticals to launch the ProteXidine® product line for boosting skin health, representing a technology commercialization partnership.
• Windgap MedicalminorStrategic or Co-development PartnerThe University of Minnesota and Windgap Medical received a $3.2 million NIH grant to develop a cyanide antidote autoinjector device. CDD researchers contributed the antidote compound technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ViiV Healthcare: HIV-focused pharmaceutical company with deep antiviral portfolio. Comparable in therapeutic focus on HIV drug development, particularly relevant given CDD's HIV capsid and nuclease inhibitor programs.
• Broad Institute: Academic research organization focused on biomedical and genomic discovery. Comparable as an academic-affiliated drug discovery center with significant NIH funding and translational research output.
• TOPIX Pharmaceuticals: Skincare and cosmetic product company that has commercialized CDD's ProteXidine™ technology. Directly comparable as the channel partner bringing CDD's dermatological/cosmetic science innovations to consumer markets.
• Retispec: Commercialization partner for CDD's hyperspectral retinal imaging technology for Alzheimer's detection. Directly comparable in Alzheimer's early-diagnostic approach and serves as the go-to-market vehicle for this CDD asset.
• Scripps Research Institute: Academic biomedical research institute with a long-standing drug discovery program. Directly comparable in its medicinal chemistry capabilities, translational research focus, and academic-to-pharma licensing model.

Emerging players

• Altoida: Digital cognitive assessment platform for early Alzheimer's and neurodegenerative disease detection. Comparable in pursuing scalable, non-invasive early-detection solutions for Alzheimer's disease.
• C2N Diagnostics: Diagnostics company developing blood-based biomarker tests for early Alzheimer's detection. Comparable in pursuing non-invasive early Alzheimer's diagnostic approaches, though via a different modality (blood vs. retinal imaging).
• Windgap Medical: Medical device company developing autoinjector delivery systems. Direct collaboration partner with CDD on the cyanide antidote autoinjector program, representing a comparable model of academic-to-commercial technology transfer.

Broad incumbents

• Gilead Sciences: Leading global antiviral pharmaceutical company with dominant HIV franchise. Comparable as an established player in CDD's primary therapeutic area of antiviral drug development and a likely licensing/partner counterparty.
• GlaxoSmithKline: Global pharmaceutical company that commercialized CDD's Ziagen (abacavir) and is a benchmark for academic-derived drug commercialization at scale. Comparable as the established pharma counterparty validating CDD's licensing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Center For Drug Design